Marcel L Verdonk1, Michael J Hartshorn
1Astex Technology Ltd, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK. m.verdonk@astex-technology.com
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Fragment-based screening is key for drug discovery. Obtaining structural data for fragment hits is essential for optimizing them into potent drug leads.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: